Insights & Resources | Pfizer CentreOne

Into a Post-COVID World: Overcoming Pharmaceutical Supply Chain Challenges and Unlocking CDMO Opportunities

In an industry that is ever-evolving, trends and opportunities unfold at every turn. Our Global Business Development Lead Tom Wilson recently spoke with CPhI Online to share his insights on recent supply chain challenges and discuss the opportunities in the CDMO space.

How has technology helped shape the innovation of drug dosage forms and support patient-centric goals?

What are the key drug dosage form trends happening in this space, and how can we expect them to change the future of patient-centric treatments? Our Director of Operations Dierdre Whelan discusses them in this piece.

Pfizer opens €300 million state-of-the-art drug manufacturing site in Freiburg, Germany

On May 24th 2022, an opening ceremony was held for the opening of Pfizer’s newest production facility in Freiburg, Germany, which has been built with Bristol-Myers Squibb (BMS).

What are the key trends and developments in injectable drug formulation and delivery?

Although the oral solid dose therapeutics market dwarfs the number of sterile injectables consumed around the world, parenteral drug administration is still growing. In this article Martin Gonzales explores the key trends and developments in injectable drug formulation and delivery.

What Makes Us Altogether Different

For over 40 years, we've been listening, solving, and guiding our partners' drug projects to success. But what makes us an altogether different kind of CDMO to work with? Find out here.

Pfizer CentreOne Wins Medicine Maker CDMO of the Year Award

The first annual CDMO of the Year Award by the Medicine Maker has wrapped up for 2022 and we’re pleased to announce that Pfizer CentreOne has been crowned the winner!

Glass Vial vs PFS Processing: What’s the Difference?

Prefilled syringes (PFS) have become an increasingly attractive choice for medical professionals, especially in recent years in this article we’ll be discussing the differences between glass vials and PFS that manufacturers must account for in their switch to PFS devices.

Transitioning from a Vial to PFS: What are the Benefits?

The development of parenteral drugs has increased significantly, with the market set to reach $1.2 billion USD by 2028¹.

Making the Move: Migrating a Drug Product from Vial to Prefilled Syringe

In this article we're continuing our conversation on migrating parenteral drug products from traditional glass vials to PFS devices, we’ll focus on the technical aspects of this change, discussing the analytical requirements and screening requirements that must be followed when migrating a drug p

CMO Leadership Awards 2022: Pfizer CentreOne Wins for Sixth Consecutive Year

Pfizer CentreOne wins CMO leadership awards for sixth consecutive year, learn what it means to the in this interview with Andrew Moore

Balancing Pressing Priorities

In the latest roundtable discussion with BioPharm International, our contract manufacturing lead Tom Wilson spoke alongside other industry leaders about these supply chain challenges and how we were able to change our business processes and develop best practices to ensure effective remote partne

Considerations for Migrating a Drug Product Presentation from Vial to Pre-Filled Syringe

This whitepaper outlines the benefits of PFS transfer, the differences between glass and PFS devices, and the key engineering processes required to successfully carry out this process.